ABSTRACT
A 44-year-old male patient underwent total gastrectomy for gastric cancer with peritoneal dissemination and direct invasion into the pancreas. After the operation, the patient received daily oral administration of TS-1, a novel oral anticancer agent. Each treatment course consisted of four-week administration of 120 mg TS-1 daily followed by two drug-free weeks. The patient was confirmed to be cancer-free by abdominal CT from the eighth course. With this chemotherapy, slight decrease of WBC (grade 1 or 2) and mild bowel obstruction appeared as the side effects of TS-1, but no other serious effects were observed. (A dose reduction of TS-1 from 120 mg to 100 mg per day was done at the beginning of the fifth course.) This patient could return to his work (physical labor) in the sixth month after the operation. The cancer-free period has persisted for sixteen months since the operation, and a good quality of life has been maintained simultaneously. TS-1 revealed a high effectiveness without deteriorating the patient's quality of life.
